Parathyroid therapy recommended

Saturday 25 February 2017

United Kingdom

The European Medicines Agency is recommending approval of Natpar (parathyroid hormone) to treat patients with chronic hypoparathyroidism who require more than calcium and vitamin D. If approved by the European Commission, Natpar would be the first hormone replacement therapy for this condition.